MetaADEDB 2.0 @ LMMD
Oxaydo
(IGNAMRAQFUFUMH-KCTCKCTRSA-N)
Structure
SMILES
COc1ccc2c3c1O[C@@H]1[C@@]43CCN[C@H](C2)[C@]4(O)CCC1=O.Cl
Molecular Formula:
C17H20ClNO4
Molecular Weight:
337.798
Log P:
1.8368
Hydrogen Bond Acceptor:
5
Hydrogen Bond Donor:
3
TPSA:
67.79
CAS Number(s):
52446-25-0
Synonym(s)
1.
Oxaydo
External Link(s)
PubChem Compound91971670
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Malignant neoplasm progressionFAERS: 9US FAERS
2Incorrect dose administeredFAERS: 7US FAERS
3PruritusFAERS: 7US FAERS
4SomnolenceFAERS: 7US FAERS
5HeadacheFAERS: 6US FAERS
6AgitationFAERS: 5US FAERS
7Drug ineffectiveFAERS: 5US FAERS
8Drug toxicityFAERS: 5US FAERS
9Feeling abnormalFAERS: 5US FAERS
10Accidental deathFAERS: 4US FAERS
11Accidental overdoseFAERS: 4US FAERS
12Disease ProgressionFAERS: 4US FAERS
13DizzinessFAERS: 4US FAERS
14Abdominal discomfortFAERS: 3US FAERS
15AnxietyFAERS: 3US FAERS
16DyspepsiaFAERS: 3US FAERS
17NauseaFAERS: 3US FAERS
18PallorFAERS: 3US FAERS
19Product quality issueFAERS: 3US FAERS
20Suspected counterfeit productFAERS: 3US FAERS
21VomitingFAERS: 3US FAERS
22Acute prerenal failureFAERS: 2US FAERS
23AstheniaFAERS: 2US FAERS
24BlindnessFAERS: 2US FAERS
25DeliriumFAERS: 2US FAERS
26Depressed Level of ConsciousnessFAERS: 2US FAERS
27Drug DependenceFAERS: 2US FAERS
28Drug level fluctuatingFAERS: 2US FAERS
29Drug withdrawal syndromeFAERS: 2US FAERS
30HypersensitivityFAERS: 2US FAERS
31Inappropriate schedule of drug administrationFAERS: 2US FAERS
32MalaiseFAERS: 2US FAERS
33OverdoseFAERS: 2US FAERS
34PainFAERS: 2US FAERS
35Product distribution issueFAERS: 2US FAERS
36Throat irritationFAERS: 2US FAERS
37Unevaluable eventFAERS: 2US FAERS
38Urinary RetentionFAERS: 2US FAERS
39UrticariaFAERS: 2US FAERS
40Visual ImpairmentFAERS: 2US FAERS
41Wrong technique in product usage processFAERS: 2US FAERS
42AbscessFAERS: 1US FAERS
43AcidosisFAERS: 1US FAERS
44Alanine Aminotransferase IncreasedFAERS: 1US FAERS
45Altered state of consciousnessFAERS: 1US FAERS
46Anaphylactic shockFAERS: 1US FAERS
47AngerFAERS: 1US FAERS
48ApathyFAERS: 1US FAERS
49Atrial FibrillationFAERS: 1US FAERS
50Blood alkaline phosphatase increasedFAERS: 1US FAERS
51Cerebral InfarctionFAERS: 1US FAERS
52Cerebrovascular accidentFAERS: 1US FAERS
53ChillsFAERS: 1US FAERS
54Circumstance or information capable of leading to medication errorFAERS: 1US FAERS
55CryingFAERS: 1US FAERS
56Depression suicidalFAERS: 1US FAERS
57Device programming errorFAERS: 1US FAERS
58DiscomfortFAERS: 1US FAERS
59Disease complicationFAERS: 1US FAERS
60DisorientationFAERS: 1US FAERS
61Drug abuseFAERS: 1US FAERS
62Drug administration errorFAERS: 1US FAERS
63Drug dose omissionFAERS: 1US FAERS
64Drug prescribing errorFAERS: 1US FAERS
65Electrolyte depletionFAERS: 1US FAERS
66Eyelid Function DisorderFAERS: 1US FAERS
67HypersomniaFAERS: 1US FAERS
68HypotensionFAERS: 1US FAERS
69Hypotonic-hyporesponsive episodeFAERS: 1US FAERS
70Incorrect drug dosage form administeredFAERS: 1US FAERS
71Incorrect route of drug administrationFAERS: 1US FAERS
72Injection site vesiclesFAERS: 1US FAERS
73Intentional product misuseFAERS: 1US FAERS
74Medication ErrorFAERS: 1US FAERS
75Medication tamperingFAERS: 1US FAERS
76Mental status changesFAERS: 1US FAERS
77Mood swingsFAERS: 1US FAERS
78Occupational exposure to productFAERS: 1US FAERS
79Personality change due to a general medical conditionFAERS: 1US FAERS
80Post procedural complicationFAERS: 1US FAERS
81Product coating issueFAERS: 1US FAERS
82Product dispensing errorFAERS: 1US FAERS
83Product physical consistency issueFAERS: 1US FAERS
84Product size issueFAERS: 1US FAERS
85Product solubility abnormalFAERS: 1US FAERS
86Respiratory distressFAERS: 1US FAERS
87Skin lesionFAERS: 1US FAERS
88Toxicity to various agentsFAERS: 1US FAERS
89TremorFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.